Trial
NCT04963270
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Hoffmann-La Roche
Collaborators
Chugai Pharmaceutical
Condition
Generalized Myasthenia Gravis
Intervention
Satralizumab
Why stopped
Sponsor decided to halt development of satralizumab in generalized myasthenia gravis and discontinued further dosing with the study drug (while the OLE period was ongoing) upon reviewing the primary results (DB period).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-28